The FDA granted accelerated approval to nivolumab for second-line treatment of advanced hepatocellular carcinoma, making it just the third drug on the market for the disease. The PD-1 inhibitor is approved for patients who cannot tolerate sorafenib and those whose disease progressed despite treatment with the multikinase inhibitor.
from Cancer via ola Kala on Inoreader http://ift.tt/2iTPUUo
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου